Back

Advantage of novel oral anticoagulants compared to vitamin-K antagonist in atrial fibrillation. Data from real world.

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 5 - Atrial fibrillation - Stroke prevention 2 Oral Anticoagulation ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Gabor Antal Simonyi

St Imre University Teaching Hospital, Budapest (Hungary)

10 More presentations in this session

Presentation thumbnail
Antithrombotic management in patients with atrial fibrillation and acute coronary syndromes
Associate Professor B. Hudzik (Zabrze, PL)
Abstract Slides
Presentation thumbnail
Prior antithrombotic therapy: a snapshot of 17,769 patients from the global edoxaban treatment in routine clinical practice in patients with non-valvular atrial fibrillation programme (global ETNA-AF)
Professor R. De Caterina (Pisa, IT)
Abstract Slides
Presentation thumbnail
Oral anticoagulation continuation vs. discontinuation after catheter-ablation of paroxysmal atrial fibrillation - incidence of cerebral insults and severe hemorrhagic complications
Ms L. Pracht (Munich, DE)
Abstract
Presentation thumbnail
A new score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
Doctor O. Rutherford (Sarpsborg, NO)
Abstract Slides
Presentation thumbnail
Difference of efficacy and safety of left atrial appendage closure using watchman between patients aged less than 75 to more than 75 years
Doctor J. Yu (Koblenz, DE)
Abstract

Access the full session

Session thumbnail
Poster Session 5 - Atrial fibrillation - Stroke prevention 2

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources